国家自然科学基金肿瘤临床及转化研究资助概况与未来展望  

Overview and Perspectives of Funding for Clinical and Translational Research in Oncology by the National Natural Science Foundation of China

作　　者：姚刚 岑栋 王斐 邢晓芳[1,4] 肖毅 石嵘 Gang Yao;Dong Cen;Fei Wang;Xiaofang Xing;Yi Xiao;Rong Shi(Department of Health Sciences,National Natural Science Foundation of China,Beijing 100085,China;Sir Run Run Shaw Hospital,Zhejiang University,Hangzhou 310016,China;The Second Hospital of Shandong University,Jinan 250033,China;Peking University Cancer Hospital,Beijing 100142,China;Fudan University Shanghai Cancer Center,Shanghai 200032,China)

机构地区：[1]国家自然科学基金委员会医学科学部,北京100085 [2]浙江大学附属邵逸夫医院,杭州310016 [3]山东大学第二医院,济南250033 [4]北京大学肿瘤医院,北京100142 [5]复旦大学附属肿瘤医院,上海200032

出　　处：《中国科学基金》2025年第1期185-192,共8页Bulletin of National Natural Science Foundation of China

摘　　要：2021年,国家自然科学基金委员会医学科学部在深入研判肿瘤学科发展趋势和广泛调研的基础上,调整设立了以科学问题为导向的肿瘤学(H18)新代码体系,其中H1801—H1811申请代码资助肿瘤基础研究,H1812—H1826申请代码资助肿瘤临床及转化研究。本文就2021—2024年肿瘤临床及转化研究方向面上类项目(包括面上项目、青年科学基金项目和地区科学基金项目)的资助情况进行回顾分析,旨在了解科学基金对该领域的资助现状、面临挑战和未来发展。In 2021,the Department of Health Sciences in the National Natural Science Foundation of China(NSFC)established a new secondary code for Oncology(H18)in response to an in-depth study of the evolving landscape within the discipline.The funding framework for oncology is now structured into two primary categories:Basic Oncology Discipline(H1801—H1811)and Clinical and Translational Oncology Discipline(H1812—H1826).This paper presents a review and analysis of the funding landscape for general projects—including the General Program,Young Scientist Fund,and Fund for Less Developed Regions—within the Clinical and Translational Oncology Discipline from 2021 to 2024.The aim of this analysis is to clarify the current status of funding,identify existing challenges,and explore future directions for clinical and translational oncology research in China.

关 键 词：国家自然科学基金 肿瘤学科 肿瘤基础 肿瘤临床与转化 

分 类 号：R73[医药卫生—肿瘤]